[go: up one dir, main page]

MX2017011121A - Uso de lavados alcalinos durante la cromatografia para remover impurezas. - Google Patents

Uso de lavados alcalinos durante la cromatografia para remover impurezas.

Info

Publication number
MX2017011121A
MX2017011121A MX2017011121A MX2017011121A MX2017011121A MX 2017011121 A MX2017011121 A MX 2017011121A MX 2017011121 A MX2017011121 A MX 2017011121A MX 2017011121 A MX2017011121 A MX 2017011121A MX 2017011121 A MX2017011121 A MX 2017011121A
Authority
MX
Mexico
Prior art keywords
remove impurities
protein
interest
during chromatography
chromatography
Prior art date
Application number
MX2017011121A
Other languages
English (en)
Other versions
MX395730B (es
Inventor
Wang Jue
E Jaffe Neil
Patel Krina
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2017011121A publication Critical patent/MX2017011121A/es
Publication of MX395730B publication Critical patent/MX395730B/es

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/10Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/20Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the sorbent material
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/10Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804Affinity chromatography
    • B01D15/3809Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/42Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424Elution mode
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/50Conditioning of the sorbent material or stationary liquid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/88Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

La presente invención se refiere en ciertas modalidades, a un método para purificar una proteína de interés a partir de una mezcla la cual comprende la proteína de interés y uno o más contaminantes, tal método comprende: a) someter la mezcla a una primera matriz de cromatografía, en donde la proteína de interés se une a la primera matriz de cromatografía; b) poner en contacto la primera matriz de cromatografía con una primera solución de lavado la cual tiene un pH de al menos 9.0, y no comprende arginina o un derivado de arginina; y c) eluir la proteína de interés a partir de la primera matriz de cromatografía en una solución de elución.
MX2017011121A 2015-03-13 2016-03-11 Uso de lavados alcalinos durante la cromatografia para remover impurezas. MX395730B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562132974P 2015-03-13 2015-03-13
PCT/US2016/021984 WO2016149088A1 (en) 2015-03-13 2016-03-11 Use of alkaline washes during chromatography to remove impurities

Publications (2)

Publication Number Publication Date
MX2017011121A true MX2017011121A (es) 2017-11-28
MX395730B MX395730B (es) 2025-03-25

Family

ID=55699796

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011121A MX395730B (es) 2015-03-13 2016-03-11 Uso de lavados alcalinos durante la cromatografia para remover impurezas.

Country Status (13)

Country Link
US (2) US10695693B2 (es)
EP (2) EP3268100A1 (es)
JP (1) JP6807859B2 (es)
KR (1) KR102490956B1 (es)
CN (1) CN107636005B (es)
AU (2) AU2016233557B2 (es)
BR (1) BR112017018365A2 (es)
CA (1) CA2978095C (es)
EA (1) EA035635B1 (es)
IL (1) IL254372B (es)
MX (1) MX395730B (es)
SG (2) SG11201707330RA (es)
WO (1) WO2016149088A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073401A1 (en) * 2014-11-03 2016-05-12 Bristol-Myers Squibb Company Use of caprylic acid precipitation for protein purification
CA2978095C (en) 2015-03-13 2022-02-15 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
KR102586771B1 (ko) 2017-01-30 2023-10-11 리제너론 파마슈티칼스 인코포레이티드 크로마토그래피에서 바이오버든을 감소시키기 위한 조성물 및 방법
KR102882390B1 (ko) * 2018-06-19 2025-11-05 브리스톨-마이어스 스큅 컴퍼니 크로마토그래피를 사용하여 단백질을 정제하는 방법
US20210382065A1 (en) * 2018-08-17 2021-12-09 Regeneron Pharmaceuticals, Inc. Method and chromatography system for determining amount and purity of a multimeric protein
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
EP4270009A3 (en) * 2018-10-31 2024-01-17 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying a protein
WO2020125757A1 (en) * 2018-12-21 2020-06-25 Wuxi Biologics (Shanghai) Co., Ltd. A method for improving aggregate removal by protein a chromatography
WO2020150328A1 (en) * 2019-01-16 2020-07-23 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying antibody fragmentation
CN109870428A (zh) * 2019-01-21 2019-06-11 江苏华泰疫苗工程技术研究有限公司 一种基于表面等离子共振技术的抗体定量检测方法
GB201904741D0 (en) * 2019-04-04 2019-05-22 Glaxosmithkline Ip Dev Ltd Novel process
WO2021061790A1 (en) 2019-09-24 2021-04-01 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
CN114599971A (zh) * 2019-10-14 2022-06-07 皮尔斯生物科技有限公司 肽纯化配制物和方法
WO2021191684A1 (en) * 2020-03-27 2021-09-30 Haemalogix Pty Ltd Composition and method
WO2025178923A1 (en) * 2024-02-20 2025-08-28 Exelixis, Inc. Methods for protein purification

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0280578B1 (en) * 1987-02-26 1993-12-15 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
US5190859A (en) * 1987-02-26 1993-03-02 Dana-Farber Cancer Institute, Inc. Purification of LFA-3
CA1323567C (en) * 1987-10-05 1993-10-26 Gene R. Nathans Method for purification of antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
PL174494B1 (pl) 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
SI1308455T1 (sl) * 1998-05-06 2006-08-31 Genentech Inc Sestavek, ki obsega protitelesa anti-HER2
KR20020047132A (ko) 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
ES2295228T3 (es) 2000-11-30 2008-04-16 Medarex, Inc. Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos.
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
US7763706B1 (en) 2003-07-17 2010-07-27 Campina B.V. Arginine/lysine-enriched peptides
PL1678208T3 (pl) 2003-10-27 2013-09-30 Wyeth Llc Usuwanie agregatów o wysokiej masie cząsteczkowej z użyciem chromatografii na hydroksyapatycie
KR101374149B1 (ko) * 2005-04-26 2014-03-14 베링거 인겔하임 에르체파우 게엠베하 운트 코 카게 융합 단백질의 자가단백질분해성 절단에 의한 재조합단백질 생산
US8263750B2 (en) * 2006-03-16 2012-09-11 Amgen Inc. Method for purifying a protein using protein-A affinity chromatography using an intermediate wash step
CA2661748C (en) * 2006-08-28 2016-02-09 Alex Eon-Duval Process for the purification of fc-containing proteins
US8350013B2 (en) 2006-09-08 2013-01-08 Wyeth Llc Arginine wash in protein purification using affinity chromatography
CN103554215B (zh) * 2007-10-30 2016-06-15 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
TW201024318A (en) * 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
MX2012007103A (es) 2009-12-18 2012-07-17 Novartis Ag Solucion y metodo de lavado por cromatografia de afinidad.
JP2012001462A (ja) * 2010-06-15 2012-01-05 Kaneka Corp 抗体精製用カラム
PT2714714T (pt) 2011-06-01 2018-10-22 Novartis Ag Solução de lavagem e método para cromatografia de afinidade
TWI596107B (zh) * 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
US9758578B2 (en) * 2013-12-26 2017-09-12 Mitsubishi Tanabe Pharma Corporation Human anti-IL-33 neutralizing monoclonal antibody
WO2016031932A1 (ja) * 2014-08-27 2016-03-03 田辺三菱製薬株式会社 アルカリ洗浄によるFc領域を有するタンパク質の製造方法
CA2978095C (en) 2015-03-13 2022-02-15 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities

Also Published As

Publication number Publication date
JP6807859B2 (ja) 2021-01-06
EP4194071A1 (en) 2023-06-14
AU2016233557B2 (en) 2021-06-24
EA035635B1 (ru) 2020-07-17
JP2018510867A (ja) 2018-04-19
AU2021221870A1 (en) 2021-09-23
IL254372B (en) 2022-05-01
IL254372A0 (en) 2017-11-30
US12157073B2 (en) 2024-12-03
KR102490956B1 (ko) 2023-01-19
AU2016233557A1 (en) 2017-11-02
CA2978095A1 (en) 2016-09-22
WO2016149088A1 (en) 2016-09-22
EA201792012A1 (ru) 2018-01-31
EP3268100A1 (en) 2018-01-17
KR20170125948A (ko) 2017-11-15
CN107636005A (zh) 2018-01-26
BR112017018365A2 (pt) 2018-04-10
SG11201707330RA (en) 2017-10-30
CN107636005B (zh) 2021-07-16
US10695693B2 (en) 2020-06-30
US20200282332A1 (en) 2020-09-10
MX395730B (es) 2025-03-25
SG10201908027QA (en) 2019-10-30
US20180078876A1 (en) 2018-03-22
CA2978095C (en) 2022-02-15

Similar Documents

Publication Publication Date Title
MX2017011121A (es) Uso de lavados alcalinos durante la cromatografia para remover impurezas.
BR112018075516A2 (pt) purificação de anticorpos multiespecíficos
AR074015A1 (es) Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica
CU20170039A7 (es) Método de purificación del anticuerpo humanizado 9e4
BR112014015101A2 (pt) cromatografia de membrana de troca iônica
MX392628B (es) Amortiguador de lavado de cromatografia de afinidad.
TR201911082T4 (tr) K vitaminine bağımlı proteinlerin saflaştırılması için bir işlem.
MX2019015304A (es) Amortiguador de lavado para cromatografia de intercambio cationico.
SG194460A1 (en) Wash solution and method for affinity chromatography
PE20142451A1 (es) Composiciones de conjugados de xten y metodos para realizar las mismas
AR062711A1 (es) Lavado de arginina en l a purificacion de proteinas usando cromatografia de afinidad
RU2014111820A (ru) Способы элиминации вируса
EP4389757A3 (en) Methods for purifying antibodies
MX2016017115A (es) Metodos y reactivos para la purificacion de proteinas.
HK1206755A1 (en) Low acidic species compositions and methods for producing and using the same
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
MX2017008410A (es) Reduccion selectiva de residuos cisteina en anticuerpos il-17.
MY181081A (en) Method for purifying antibody having low isoelectric point
MX372711B (es) Metodos para la purificacion de arilsulfatasa a.
EA202090262A1 (ru) Очистка белка
EA201892643A1 (ru) Способ очистки и активации ботулинического нейротоксина
EA201891990A1 (ru) Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна
CY1120353T1 (el) Αφαιρεση διαρρεοντος προσδεματος καθαρισμου συγγενειας
WO2015036917A3 (en) Methods and kits for quantifying the removal of mock virus particles from a purified solution
BR112018013153A2 (pt) método para a purificação de ácidos nucleicos, kit para purificar ácidos nucleicos e cartucho para executar o método